What is Leerink Partnrs’ Estimate for INSP FY2024 Earnings?

Inspire Medical Systems, Inc. (NYSE:INSP) – Equities researchers at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of Inspire Medical Systems in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $1.37 for the year, down from their previous forecast of $1.38. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q2 2025 earnings at $0.40 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $1.73 EPS and FY2026 earnings at $2.62 EPS.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.06 by $0.54. The business had revenue of $203.20 million during the quarter, compared to the consensus estimate of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. The company’s revenue was up 32.6% on a year-over-year basis. During the same period in the previous year, the business earned ($0.29) earnings per share.

Several other analysts have also recently commented on INSP. Stifel Nicolaus reissued a “hold” rating and set a $200.00 target price (up previously from $170.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Wells Fargo & Company increased their target price on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Robert W. Baird upped their target price on shares of Inspire Medical Systems from $240.00 to $252.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Piper Sandler restated an “overweight” rating and issued a $260.00 target price (up previously from $255.00) on shares of Inspire Medical Systems in a report on Tuesday, November 5th. Finally, KeyCorp reduced their target price on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $233.58.

Inspire Medical Systems Stock Down 5.2 %

Shares of Inspire Medical Systems stock opened at $189.05 on Wednesday. The stock has a market cap of $5.67 billion, a price-to-earnings ratio of 176.68 and a beta of 1.36. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40. The company’s fifty day moving average is $199.01 and its 200 day moving average is $175.73.

Hedge Funds Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the business. SouthState Corp purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $27,000. True Wealth Design LLC bought a new stake in Inspire Medical Systems in the 3rd quarter valued at $30,000. Farther Finance Advisors LLC boosted its holdings in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Inspire Medical Systems by 559.3% during the 3rd quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock valued at $38,000 after purchasing an additional 151 shares during the last quarter. Finally, Quarry LP increased its holdings in shares of Inspire Medical Systems by 105.4% in the second quarter. Quarry LP now owns 343 shares of the company’s stock worth $46,000 after purchasing an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insiders Place Their Bets

In other news, Director Shawn Mccormick sold 800 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at $5,090,800. The trade was a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.